Commercial Launch of QuickFISH™ Includes Gram Negative BC Assay
Gram-Negative QuickFISH BC is a new rapid molecular diagnostic test that identifies potentially life threatening bloodstream infections caused by Escherichia coli, and/or Pseudomonas aeruginosa and/or Klebsiella pneumoniae, within 20 minutes of a positive blood culture, making it the fastest method of identifying gram-negative species in positive blood cultures on the market today.
The new gram-negative assay is immediately available and further expands AdvanDx's QuickFISH Platform that can now identify the pathogens responsible for 90% of positive blood cultures.1 The announcement of the commercial launch of Gram-Negative QuickFISH BC adds to AdvanDx's two gram-positive QuickFISH tests: Staphylococcus QuickFISH BC for the identification of Staphylococcus aureus and/or coagulase-negative staphylococci; and Enterococcus QuickFISH BC, for the identification of Enterococcus faecalis and/or selected other enterococci. AdvanDx anticipates commercial launch of the fourth QuickFISH assay for identification of Candida species from positive blood cultures in the second half of 2013, following regulatory clearance.
QuickFISH is a new, rapid, molecular diagnostic platform developed by AdvanDx based on its clinically- proven, proprietary PNA technology. The new platform enables unprecedented (20 minute) species identification of bacteria directly from positive blood cultures, allowing the reporting of pathogen identification at the same time as the reporting of Gram stain results.
1 - Ann Clin Microbiol Antimicrob. 2004 May 10;3:7.
Source: AdvanDx View latest company information
Posted: August 26, 2013
[will open your email client]